James B Dale1, Pierre R Smeesters2, Harry S Courtney3, Thomas A Penfound3, Claudia M Hohn3, Jeremy C Smith4, Jerome Y Baudry4. 1. Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States; Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, United States; Department of Veterans Affairs Medical Center, Memphis, TN, United States. Electronic address: jbdale@uthsc.edu. 2. Department of Pediatrics, Academic Children Hospital Queen Fabiola, Université Libre de Bruxelles, Brussels, Belgium; Molecular Bacteriology Laboratory, Université Libre de Bruxelles, Brussels, Belgium; Group A Streptococcus Research Group, Murdoch Childrens Research Institute, Melbourne, Australia; Centre for International Child Health, University of Melbourne, Melbourne, Australia. 3. Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States. 4. Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Oak Ridge, TN, United States; University of Tennessee/Oak Ridge National Laboratory Center for Molecular Biophysics, Oak Ridge, TN, United States.
Abstract
BACKGROUND: A major obstacle to the development of broadly protective M protein-based group A streptococcal (GAS) vaccines is the variability within the N-terminal epitopes that evoke potent bactericidal antibodies. The concept of M type-specific protective immune responses has recently been challenged based on the observation that multivalent M protein vaccines elicited cross-reactive bactericidal antibodies against a number of non-vaccine M types of GAS. Additionally, a new "cluster-based" typing system of 175M proteins identified a limited number of clusters containing closely related M proteins. In the current study, we used the emm cluster typing system, in combination with computational structure-based peptide modeling, as a novel approach to the design of potentially broadly protective M protein-based vaccines. METHODS: M protein sequences (AA 16-50) from the E4 cluster containing 17 emm types of GAS were analyzed using de novo 3-D structure prediction tools and the resulting structures subjected to chemical diversity analysis to identify sequences that were the most representative of the 3-D physicochemical properties of the M peptides in the cluster. Five peptides that spanned the range of physicochemical attributes of all 17 peptides were used to formulate synthetic and recombinant vaccines. Rabbit antisera were assayed for antibodies that cross-reacted with E4 peptides and whole bacteria by ELISA and for bactericidal activity against all E4GAS. RESULTS: The synthetic vaccine rabbit antisera reacted with all 17 E4M peptides and demonstrated bactericidal activity against 15/17 E4GAS. A recombinant hybrid vaccine containing the same E4 peptides also elicited antibodies that cross-reacted with all E4M peptides. CONCLUSIONS: Comprehensive studies using structure-based design may result in a broadly protective M peptide vaccine that will elicit cluster-specific and emm type-specific antibody responses against the majority of clinically relevant emm types of GAS. Copyright Â
BACKGROUND: A major obstacle to the development of broadly protective M protein-based group A streptococcal (GAS) vaccines is the variability within the N-terminal epitopes that evoke potent bactericidal antibodies. The concept of M type-specific protective immune responses has recently been challenged based on the observation that multivalent M protein vaccines elicited cross-reactive bactericidal antibodies against a number of non-vaccine M types of GAS. Additionally, a new "cluster-based" typing system of 175M proteins identified a limited number of clusters containing closely related M proteins. In the current study, we used the emm cluster typing system, in combination with computational structure-based peptide modeling, as a novel approach to the design of potentially broadly protective M protein-based vaccines. METHODS: M protein sequences (AA 16-50) from the E4 cluster containing 17 emm types of GAS were analyzed using de novo 3-D structure prediction tools and the resulting structures subjected to chemical diversity analysis to identify sequences that were the most representative of the 3-D physicochemical properties of the M peptides in the cluster. Five peptides that spanned the range of physicochemical attributes of all 17 peptides were used to formulate synthetic and recombinant vaccines. Rabbit antisera were assayed for antibodies that cross-reacted with E4 peptides and whole bacteria by ELISA and for bactericidal activity against all E4GAS. RESULTS: The synthetic vaccine rabbit antisera reacted with all 17 E4M peptides and demonstrated bactericidal activity against 15/17 E4GAS. A recombinant hybrid vaccine containing the same E4 peptides also elicited antibodies that cross-reacted with all E4M peptides. CONCLUSIONS: Comprehensive studies using structure-based design may result in a broadly protective M peptide vaccine that will elicit cluster-specific and emm type-specific antibody responses against the majority of clinically relevant emm types of GAS. Copyright Â
Authors: Mary C Hu; Michael A Walls; Steven D Stroop; Mark A Reddish; Bernard Beall; James B Dale Journal: Infect Immun Date: 2002-04 Impact factor: 3.441
Authors: Stanford T Shulman; Robert R Tanz; James B Dale; Bernard Beall; William Kabat; Kathleen Kabat; Emily Cederlund; Devendra Patel; Jason Rippe; Zhongya Li; Varja Sakota Journal: Clin Infect Dis Date: 2009-07-01 Impact factor: 9.079
Authors: Martina Sanderson-Smith; David M P De Oliveira; Julien Guglielmini; David J McMillan; Therese Vu; Jessica K Holien; Anna Henningham; Andrew C Steer; Debra E Bessen; James B Dale; Nigel Curtis; Bernard W Beall; Mark J Walker; Michael W Parker; Jonathan R Carapetis; Laurence Van Melderen; Kadaba S Sriprakash; Pierre R Smeesters Journal: J Infect Dis Date: 2014-05-05 Impact factor: 5.226
Authors: Karen L Kotloff; Mary Corretti; Kathleen Palmer; James D Campbell; Mark A Reddish; Mary C Hu; Steven S Wasserman; James B Dale Journal: JAMA Date: 2004-08-11 Impact factor: 56.272
Authors: Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet Journal: Clin Microbiol Rev Date: 2014-04 Impact factor: 26.132
Authors: Jay A Spencer; Tom Penfound; Sanaz Salehi; Michelle P Aranha; Lauren E Wade; Rupesh Agarwal; Jeremy C Smith; James B Dale; Jerome Baudry Journal: Vaccine Date: 2021-02-26 Impact factor: 3.641
Authors: Michelle P Aranha; Thomas A Penfound; Jay A Spencer; Rupesh Agarwal; Jerome Baudry; James B Dale; Jeremy C Smith Journal: J Biol Chem Date: 2020-02-06 Impact factor: 5.157
Authors: Aniela Wozniak; Natalia Scioscia; Patricia C García; James B Dale; Braulio A Paillavil; Paulette Legarraga; Francisco J Salazar-Echegarai; Susan M Bueno; Alexis M Kalergis Journal: Microbiol Immunol Date: 2018-06-11 Impact factor: 1.955
Authors: Sandra J Valenciano; Jennifer Onukwube; Michael W Spiller; Ann Thomas; Kathryn Como-Sabetti; William Schaffner; Monica Farley; Susan Petit; James P Watt; Nancy Spina; Lee H Harrison; Nisha B Alden; Salina Torres; Melissa L Arvay; Bernard Beall; Chris A Van Beneden Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079
Authors: Michelle P Aranha; Thomas A Penfound; Sanaz Salehi; Anne Botteaux; Pierre Smeesters; James B Dale; Jeremy C Smith Journal: J Immunol Date: 2021-08-02 Impact factor: 5.426